GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Viltolarsen (VILTEPSO)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug1 sources available - open source summaries, references and comparisons

Viltolarsen (Viltepso)

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Low muscle mass and assay interference can mislead renal monitoring

The VILTEPSO source cautions that creatinine is unreliable in low-muscle-mass DMD and that excreted drug can interfere with a urine-protein reagent. A low creatinine or positive protein result may need additional interpretation.

Before applying: Follow the source-specific cystatin-C and urine monitoring plan, specimen timing and assay guidance. Do not turn a potentially misleading estimate into a new dose-reduction algorithm.

Also check: Low muscle mass and assay interference can mislead renal monitoring

Rxlist source

GlobalRPh RX List - Viltolarsen (Viltepso)

Product / population
VILTEPSO for Duchenne muscular dystrophy amenable to exon 53 skipping; kidney monitoring and evidence gap.
Renal measure
Low muscle mass limits creatinine-based estimates; cystatin C, urine protein and possible exogenous-marker GFR.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

No renal dose recommendation is established for impaired kidney function. Before treatment obtain cystatin C, urine dipstick and urine protein-to-creatinine ratio, and consider an exogenous-marker GFR. During treatment check urine dipstick monthly and cystatin C/protein ratio every three months. For urine protein testing, use a pre-infusion specimen or one at least 48 hours after infusion, or an assay avoiding pyrogallol red, because excreted drug can interfere. Persistent cystatin-C or protein increases warrant pediatric-nephrology assessment. Low muscle mass in DMD makes serum creatinine an unreliable basis for an invented reduction.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/viltepso-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Viltolarsen (Viltepso)

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

VILTEPSO for Duchenne muscular dystrophy amenable to exon 53 skipping; kidney monitoring and evidence gap.

Renal method: Low muscle mass limits creatinine-based estimates; cystatin C, urine protein and possible exogenous-marker GFR.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measurement monitoring

Low muscle mass and assay interference can mislead renal monitoring

The VILTEPSO source cautions that creatinine is unreliable in low-muscle-mass DMD and that excreted drug can interfere with a urine-protein reagent. A low creatinine or positive protein result may need additional interpretation.

How to use this: Follow the source-specific cystatin-C and urine monitoring plan, specimen timing and assay guidance. Do not turn a potentially misleading estimate into a new dose-reduction algorithm.

GlobalRPh RX List - Viltolarsen (Viltepso)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - Viltolarsen (Viltepso)
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/viltepso-drug/

Exact product and population

VILTEPSO for Duchenne muscular dystrophy amenable to exon 53 skipping; kidney monitoring and evidence gap.

RDM40-SCOPE-viltolarsen-viltepso · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Viltolarsen (Viltepso)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · VILTEPSO for Duchenne muscular dystrophy amenable to exon 53 skipping; kidney monitoring and evidence gap.

Renal method: Low muscle mass limits creatinine-based estimates; cystatin C, urine protein and possible exogenous-marker GFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal dose recommendation is established for impaired kidney function. Before treatment obtain cystatin C, urine dipstick and urine protein-to-creatinine ratio, and consider an exogenous-marker GFR. During treatment check urine dipstick monthly and cystatin C/protein ratio every three months. For urine protein testing, use a pre-infusion specimen or one at least 48 hours after infusion, or an assay avoiding pyrogallol red, because excreted drug can interfere. Persistent cystatin-C or protein increases warrant pediatric-nephrology assessment. Low muscle mass in DMD makes serum creatinine an unreliable basis for an invented reduction.

RDM40-rxlist-viltolarsen-viltepso-08f0d51c1a-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/viltepso-drug/
Retrieved
2026-09-07
Renal-function method
Low muscle mass limits creatinine-based estimates; cystatin C, urine protein and possible exogenous-marker GFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
6a165a9f7add3ec976a1edf9da204cf78ec101a44e902e4eba08643b2fba281a

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/viltepso-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
7a8b084b8934af1b1b1b25bb0623687807273af4b8a9850c9d544feca10b8fb8
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report